Mumbai, Baltimore, August 16, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the US. Tiotropium Bromide Inhalation Powder, 18 mcg/capsule is a generic equivalent of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule of Boehringer Ingelheim Pharmaceuticals, Inc.
With this launch, Lupin introduces an alternative to combat COPD, a condition impacting over 15 million adults in the US and ranked as the fourth leading cause of death in the country. By extending enhanced accessibility to cutting-edge products, Lupin actively contributes to alleviating the burden of COPD for patients across the nation. Read more >
Lupin is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD Lupin is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.
